Investigating the Molecular Basis for Drug Resistance and Disease Relapse in Myelodysplastic Syndromes

研究骨髓增生异常综合征耐药性和疾病复发的分子基础

• 批准号: nhmrc : GNT1139787
• 负责人: A/Pr Jason Wong
• 金额: $ 72.26万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigating-molecular-basis-myelodysplastic-syndromes/1348256
• 关键词: Investigating; Molecular; Basis; Drug; Resistance

Myelodysplastic Syndromes (MDS) are a group of blood stem cell disorders that result in low blood counts and leukemia especially in the elderly. Azacitidine (AZA) is a drug that improves blood counts and delays progression to leukemia and is the treatment of choice. However, only half the patients treated with AZA ever respond and half of the responders relapse within a year. We will describe the origins of MDS and the basis for drug response, resistance and disease relapse.

骨髓增生异常综合征(MDS)是一组血液干细胞疾病，导致低血球和白血病，尤其是在老年人。阿扎替丁(AZA)是一种可以改善血细胞计数并延缓白血病进展的药物，是治疗白血病的首选药物。然而，接受AZA治疗的患者中只有一半有反应，有一半的应答者在一年内复发。我们将描述MDS的起源以及药物反应、耐药性和疾病复发的基础。